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Abstract
OBJECTIVE: To observe if integrated treatment is
better than other therapies for lower-limb stageⅡ
thromboangiitis obliterans (TAO).
METHODS: Ninety lower-limb stage Ⅱ or worse
TAO patients were randomly divided into three
groups: group A (30 cases) treated by intervention
and oral administration of Chinese medicine; group
B (30 cases) treated by intervention alone; and
group C (30 cases) treated only with oral adminis-
tration of Chinese medicine. Therapeutic effects
were observed, including the cure rate; the recur-
rence rate after one month, three months, six
months, nine months, and one year; the ankle bra-
chial indexes; the incidence of complications; and
the level of C-reactive protein and erythrocyte sedi-
mentation rate.
RESULTS: Group A had significantly better clinically
curative effects, related indexes, and outcomes dur-
ing the long-term follow-up survey, than that of
groups B and C.
CONCLUSION: Integrated treatment is more effec-
tive for treating lower-limb stageⅡ or worse TAO.
© 2015 JTCM. All rights reserved.
Key words: Thromboangiitis obliterans; Lower ex-
tremity; Intervention studies; Medicine, Chinese tra-
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INTRODUCTION
Thromboangiitis obliterans (TAO), also called Buerg-
er's disease, is a chronic occlusive disease characterized
by segmental and nonpurulent inflammation in the
small and medium-sized arteries and veins and with
thrombosis of the arteries. The tibial and fibular arter-
ies are most frequently involved, with ischemic lesions
on the distal side of the affected limb. The pathogene-
sis of thromboangiitis obliterans is still uncertain, but
it usually affects men under the age of 45. Most studies
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have pointed out that tobacco is one of the most im-
portant predisposing factors.1-3 Therefore, the stage Ⅱ
TAO patients should quit smoking. Aside from smok-
ing cessation, many other methods of treatment can be
adopted, such as drug therapy, surgical revasculariza-
tion, endarterectomy, autologous bone marrow mono-
nuclear cell transplantation, staying warm, and increas-
ing of physical exercise.4-10 It is very difficult to relieve
ischemia and open blocked arteries for stage Ⅱ TAO
patients. Endovascular interventional treatment can sig-
nificantly enhance the limb salvage rate and reduce the
disability rate, but the long-term patency rate is rather
low.11,12 It has been shown that Chinese medicine can
relieve ischemia by improving local blood circulation
and removing blood stasis, and it can prevent resteno-
sis after percutaneous transluminal angioplasty
(PTA).13-15 At present, PTA is used for the treatment of
thromboangiitis obliterans.16 The present study was de-
signed to investigate an integrated treatment to open
blocked arteries and maintain a long-term curative ef-
fect for stage Ⅱ or worse TAO patients. We hypothe-
sized that an integrated treatment by interventional ap-
proach and oral administration of Chinese medicine
can yield better results than other therapies.
MATERIALS ANDMETHODS
General data
Ninety patients with stage Ⅱ or worse lower-limb
thromboangiitis obliterans were admitted to the First
Affiliated Hospital of Lanzhou University from Janu-
ary 2009 to June 2012. Patients were randomly divid-
ed into three groups according to the number admitted
to the hospital: group A (30 cases) treated by interven-
tion and oral administration of Chinese medicine;
group B (30 cases) treated only by intervention; and
group C (30 cases) treated with Chinese medicine
alone. The percentage of limb salvage, pain-relieving ef-
ficacy, ankle brachial indexes (ABI) before and after
treatment, incidence of complications, recurrence rate,
level of C-reactive protein, and erythrocyte sedimenta-
tion rate (ESR) were analyzed. Patients in the three
groups were followed up for at least one year. This
study was conducted in accordance with the Declara-
tion of Helsinki, and with an approval from the Ethics
Committee of the First Affiliated Hospital of Lanzhou
University. Written informed consent was obtained
from all the patients. The Traditional Chinese Medi-
cine (TCM) syndrome differentiation for the patients
was made by one experienced TCM professor with
over 30 years of experience.
Diagnostic criteria
Patients in each group were diagnosed using the Diag-
nostic Criteria for Thromboangiitis Obliterans revised
in 1995 by the Peripheral Vascular Disease Committee
under China Society of Integrated Traditional Chinese
and Western Medicine.17
Inclusion criteria
(a) Patients who suffered from stage Ⅱ or worse low-
er-limb thromboangiitis obliterans and had not re-
ceived surgical operation or intervention before admit-
tance; (b) the iliac and femoral arteries were not in-
volved; (c) patients willingly signed the Treatment Con-
sent Form; (d) liver and kidney functions were normal
without marked tendency of bleeding; (e) patients sur-
vived at least one year after treatment, and were willing
to follow up.
Therapeutic methods
Interventional therapy: the ipsilateral femoral artery
was selected for antegrade puncture with a vascular
sheath inserted, and arteriography was performed as-
sess the legion range. Then, a straight catheter was in-
serted under a guide wire and retained for 3 days with
urokinase (0.3 million U, Livzon Pharmaceutical Facto-
ry) injected twice a day. Three days later, arteriography
was performed again to reassess the legion range and
decide which size of deep balloon dilation catheter
should be used. The balloon angioplasty was per-
formed on the affected limb, and the balloon dilatation
lasted 3 min each time. After the dilation, the straight
catheter was inserted again to inject urokinase for three
days. Meanwhile, 0.4 mL of low molecular weight hep-
arin was injected subcutaneously twice a day for 7-14
days. Finally, 100 mg oral aspirin (Bayer Health Care)
was prescribed to each patient for life, to prevent plate-
let aggregation.
Oral administration of Chinese medicine: for Yin-cold-
ness syndrome, the affected limb was cold, and the pa-
tient had an obvious aversion to cold. There was a whit-
ish or flush local skin surface, the tongue was pale,
with a thin whitish coating, and the patient's pulse was
deep and thready. The therapeutic principle included
warming the meridians to dispel the coldness, and pro-
moting blood flow to remove the obstruction in the
channels and collaterals. The prescription used was
modified Yanghe Tang: Shudihuang (Radix Rehmanni-
ae Praeparata) 30 g, Huangqi (Radix Astragali Mongoli-
ci) 30 g, Jixueteng (Caulis Spatholobi) 30 g, Dangshen
(Radix Codonopsis) 15 g, Danggui (Radix Angelicae Si-
nensis) 15 g, Ganjiang (Rhizoma Zingiberis) 15 g, Ch-
ishao (Radix Paeoniae Rubra) 15 g, Niuxi (Radix Achy-
ranthis Bidentatae) 15 g, Rougui (Cortex Cinnamomi)
10 g, Baijiezi (Semen Sinapis Albae) 10 g, Fuzi (Radix
Aconiti Lateralis Preparata) 10 g, Gancao (Radix Glycyr-
rhizae) (prepared) 10 g, Dilong (Pheretima Aspergillum)
15 g, Mahuang (Herba Ephedra Sinica) 6 g, and Luji-
aoshuang (Cornu Cervi Degelatinatum)10 g (all of Chi-
nese herbal medicine purchased from the First Affiliat-
ed Hospital of Lanzhou University of TCM pharmacy).
For blood-stasis syndrome, the patient had fixed persis-
tent pain on the affected limb, with purplish red, dark
red, or dark blue local skin surface. The patient's
tongue was dark red or dark purple, with a white coat-
ing or possibly with petechiae, and the pulse was deep,
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thready, and uneven. The therapeutic principle was
promoting blood flow to dissolve blood stasis, and re-
move the obstruction in the channels and collaterals to
relieve pain. The prescription used was Modified Huox-
uetongmai decoction (decoction for promoting the
blood flow to remove the obstruction in the collater-
als): Danshen (Radix Salviae Miltiorrhizae) 30 g, Ch-
ishao (Radix Paeoniae Rubra) 60 g, Jinyinhua (Flos
Lonicerae) 30 g, Tufuling (Rhizoma Smilacis Chinae)
60 g, Danggui (Radix Angelicae Sinensis) 15 g, Chuanx-
iong (Rhizoma Chuanxiong) 15 g, Niuxi (Radix Achy-
ranthis Bidentatae) 15 g, Jixueteng (Caulis Spatholobi)
15 g, Pugongying (Herba Taraxaci) 30 g, and Banlan-
gen (Radix Isatidis) 15 g.
For damp-heat syndrome, the affected limb was flush
or purplish red in color with swelling and pain, and
with ulcers on the toes. The patient had gangrene with
mild inflammation, or superficial migratory thrombo-
phlebitis on the affected limb. The patient's tongue
was reddish with a yellowish thick or greasy coating,
and the pulse was slippery and rapid. The therapeutic
principle included clearing the heat and dispelling
dampness, and activating blood flow to dissolve blood
stasis. The prescription used was modified Simiaoyon-
gan Tang: Jinyinhua (Flos Lonicerae) 30 g, Xuanshen
(Radix Scrophulariae) 30 g, Danggui (Radix Angelicae
Sinensis) 15 g, Chishao (Radix Paeoniae Rubra) 15 g,
Niuxi (Radix Achyranthis Bidentatae) 15 g, Huangbai
(Cortex Phellodendri Amurensis) 10 g, Huangqin (Radix
Scutellariae Baicalensis) 10 g, Lianqiao (Fructus Forsyth-
iae Suspensae) 10 g, Cangzhu (Rhizoma Atractylodis
Lanceae) 10 g, Zicao (Radix lithospermi) 10 g, and Gan-
cao (Radix Glycyrrhizae) 10 g.
For heat-toxicity syndrome, the patient had gangrene
of the affected limb, ulcers with secondary severe infec-
tion, swelling and pain with feverish sensation, abun-
dant and smelly suppuration (the pain was so severe
that the patient was sitting with the affected foot held
in hands, unable to sleep). These symptoms were ac-
companied with feverish sensation of the whole body
or high fever, aversion to cold, polydipsia, and constipa-
tion with scanty dark red urine. The patient's tongue
was dark red with yellowish and dry or black coating,
and the pulse was taut and rapid or thready and rapid.
The therapeutic principle included clearing away heat
to remove toxins, and nourishing Yin to activate blood
circulation. The prescription used was modified Simi-
aohuoxue Tang (decoction of Four Miraculous Herbs):
Jinyinhua (Flos Lonicerae) 30 g, Pugongying (Herba Ta-
raxaci) 30 g, Xuanshen (Radix Scrophulariae) 15 g,
Danggui (Radix Angelicae Sinensis) 15 g, Huangqi (Ra-
dix Astragali Mongolici) 15 g, Danshen (Radix Salviae
Miltiorrhizae) 15 g, Niuxi (Radix Achyranthis Bidenta-
tae) 12 g, Lianqiao (Fructus Forsythiae Suspensae) 12 g,
Fangji (Radix Stephaniae Tetrandrae) 12 g, Huangbai
(Cortex Phellodendri Amurensis) 10 g, Huangqin (Radix
Scutellariae Baicalensis) 10 g, Honghua (Flos Carthami)
10 g, Ruxiang (Olibanum) 10 g, Moyao (Myrrh) 3 g,
Diding (Viola Japonica Langsd) 30 g, Dihuang (Radix
Rehmanniae) 15 g, Loulu (Radix Rhapontici) 12 g, and
Guanzhong (RhizomaDryopteridis Crassirhizomatis) 10 g.
For Qi and blood deficiency syndrome, the patient
was weak after prolonged disease, with muscular atro-
phy of the affected limb, and ulcers on the toes with
lucid pus. The patient's tongue was pale with thin
and whitish coating, and the patient's pulse was deep
and thready. The therapeutic principle included toni-
fying Qi, nourishing blood, and regulating and nour-
ishing the defensive Qi. The prescription used was
modified Gubu Tang: Huangqin (Radix Scutellariae
Baicalensis) 30 g, Dangshen (Radix Codonopsis) 30 g,
Jixueteng (Caulis Spatholobi) 30 g, Shihu (Dendrobi-
um nobile) 30 g, Danggui (Radix Angelicae Sinensis)
15 g, Danshen (Radix Salviae Miltiorrhizae) 15 g,
Chishao (Radix Paeoniae Rubra) 15 g, Niuxi (Radix
Achyranthis Bidentatae) 15 g, Baizhu (Rhizoma Atrac-
tylodis Macrocephalae) 15 g, and prepared Gancao
(Radix Glycyrrhizae) 10 g.
Each prescription was decocted with water for oral ad-
ministration once a day for 15 days. The integrated
treatment by interventional therapy and oral adminis-
tration of Chinese medicine was performed in Group
A. Group B was treated only by interventional therapy,
while group C was treated with oral administration of
Chinese medicine alone. After discharge from the hos-
pital, the patients in groups A and C were given a spe-
cial prescription of Chinese medicine for oral adminis-
tration once every other day for tonifying Qi, activat-
ing blood circulation, and removing stagnation until
the follow-up survey was ended.
Assessment of the indexes
The effects were evaluated by referring to the therapeu-
tic standards stipulated in 1995 by Specialty Commit-
tee of Peripheral Vascular Disease of the Chinese Asso-
ciation of Integrated Traditional Chinese and Western
Medicine.16
Clinically cured was defined as disappearance of clini-
cal symptoms and signs, with obvious improvement in
blood circulation on the distal end of the affected limb.
The patient could walk 100-200 steps per minute for a
distance of 1500 meters with no discomfort. Markedly
effective was defined as obvious amelioration of clinical
symptoms and signs, with certain improvement in
blood circulation on the distal end of the affected limb.
The patient could walk 100-120 steps per minute for a
distance at least 500 meters. Improved was defined as
alleviation of clinical symptoms and signs, with im-
provement in blood circulation on the distal end of the
affected limb. The patient could walk 100-120 steps
per minute for a distance of more than 300 meters. In-
effective was defined as No improvement is found in
the symptoms and signs, or the disease condition is ag-
gravated. Ineffective was defined as no improvement in
symptoms and signs, or aggravation of the disease
condition.
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Follow-up survey
All patients were followed up by phone or by
face-to-face interview at the first, third, sixth, ninth
and twelfth month after discharge from the hospital.
The items to check in the follow-ups included isch-
emic symptoms, walking distance with or without
limp, recurrence rate, and medicines administered. The
following indexes were detected: before and after inter-
vention, incidence of complications, level of C-reactive
protein, and ESR.
Statistical analysis
The software SPSS 18.0 (IBM, Armonk, NY, USA)
was used for statistical analysis. Chi-square test and
analysis of variance were used to analyze the difference
between groups (α = 0.05).
RESULTS
Clinical cure rate
As shown in Table 1, compared with groups B and C,
the cure rate was markedly higher in group A (P <
0.05). Compared with groups A and B, group C had a
much lower cure rate (P < 0.05).
Results of follow-up survey
The recurrence rate in group A was much lower than
that of the other two groups (P < 0.05), and the differ-
ence was much more significant at the sixth month to
one year follow-up (Table 2). To a large extent, the inte-
grated treatment enhanced the postoperative patency
rate, and reduced the recurrence rate.
Changes in indexes
For ABI, compared with groups B and C, the integrat-
ed treatment in group A showed better efficacy for im-
proving artery occlusion (P < 0.05). Compared with
groups B and C, group A had a lower incidence of
complications (P < 0.05). After treatment, the levels of
C-reactive protein and ESR in the three groups were
all lower than before treatment, especially in group A
(P < 0.05). The results indicate that the integrated
treatment may yield a better curative effect with lower
incidence of complications (Table 3).
DISCUSSION
In group A, after intervention, oral administration of
Chinesemedicine was used to consolidate the therapeutic
Group
A
B
C
Clinical cure
28
20a
5ab
Marked effectiveness
2
7
7
Improvement
0
2
12
Ineffectiveness
0
1
6
Notes: group A treated by intervention and oral administration of Chinese medicine; group B treated by intervention alone; group C treat-
ed only with oral administration of Chinese medicine. Compared with group A, aP < 0.05; compared with group B, bP < 0.05.
Table 1 Results of efficacies (n)
Notes: group A treated by intervention and oral administration of Chinese medicine; group B treated by intervention alone; group C treat-
ed only with oral administration of Chinese medicine. R: recurrence; N: no recurrence. The recurrence rate of group A is much lower than
that of the other two groups in each of the follow-up period (P < 0.05).
Group
A
B
C
1st month
R
0
1
8
N
30
29
22
3rd month
R
1
3
13
N
29
27
17
6th month
R
3
6
16
N
27
24
14
9th month
R
4
9
20
N
26
21
10
1 year
R
7
13
23
N
23
17
7
Table 2 Results of follow-up survey (n)
Parameter
ABI
C-rp (mg/L)
ESR
Treatment
Before
After
Before
After
Before
After
A
0.55±0.07
0.97±0.44ab
17.57±2.73
7.70±0.47ab
33.83±6.24
12.10±2.90ab
B
0.55±0.08
0.94±0.36ab
17.80±2.24
15.60±3.11 a
33.27±6.41
28.63±5.61a
C
0.54±0.07
0.62±0.08a
17.87±2.58
12.00±1.47ab
31.43±6.57
16.13±3.84ab
Table 3 Results of indexes before and after the treatment ( xˉ ± s)
Notes: group A treated by intervention and oral administration of Chinese medicine; group B treated by intervention alone; group C treat-
ed only with oral administration of Chinese medicine. ABI: ankle brachial indexes; ESR: erythrocyte sedimentation rate. Compared with
before treatment, there was a significant difference between group A and groups B and C after treatment (aP < 0.05, bP < 0.05).
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effects to enhance long-term efficacy. Such an integrat-
ed treatment can help to prevent thrombosis and block-
age. The basic interventional procedure is to insert a
balloon into the blood vessel and expand the thickened
arterial wall to enlarge the vascular lumen, thus main-
taining free circulation of the blood. intervention has
the following advantages: simple operation with mini-
mal invasion, a high success rate, few complications,
and repeatability.17-19 PTA has become the first choice
for patients with severe lower-limb ischemia and inter-
mittent claudication, which is successful in clinical tri-
als.20,21 In the past, many scholars believed that the
long-term patency rate was low after PTA treatment.
However, it can significantly enhance the limb salvage
rate.22,23 In the present study, an integrated treatment
was adopted with administration of an oral Chinese
medicine after intervention. The integrated treatment
may help to improve elasticity of the blood vessel, pro-
mote blood circulation, reduce platelet aggregation,
prevent coagulation, regulate immunity, fight against
free radicals, dilate the blood vessel, and relieve spasms
and pain.26-31
The results from the present study showed that com-
pared with groups B and C, the cure rate in group A
was markedly enhanced (P < 0.05). Meanwhile, group
C had a much lower cure rate (P < 0.05). We showed
that the problem of restenosis after intervention can be
mitigated by integrated treatment with interventional
therapy and oral administration of Chinese medicine.
With intervention followed by oral administration of
Chinese medicine, the ankle brachial index in group A
was obviously higher, and most of the values detected
were within the normal or critical range (ABI: 0.97 ±
0.04). TAO is a chronic occlusive disease characterized
by periodic nonsuppurative inflammation of the small
and medium-sized arteries and clotting of the arteries.
After treatment, the level of C-reactive protein and
ESR of all the three groups were lower, especially in
group A (P < 0.05). During the follow-up survey for at
least one year, the recurrence rate was much lower in
group A than that in groups B and C (P < 0.05), and
the difference was much more significant from sixth
months to one year after treatment. To a large extent,
the integrated treatment can enhance the postoperative
patency rate and lower the recurrence rate of the disease.
The results from the present study suggests that inte-
grated treatment can obtain satisfactory therapeutic ef-
fects with higher clinical cure rate and better indexes
than the interventional therapy or oral Chinese medi-
cine used alone for stageⅡ or worse lower-limb throm-
boangiitis obliterans. Therefore, integrated treatment
can be clinically recommended.
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